Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Yi Lin, MD
Yi Lin, MD, is from the Mayo Clinic in Rochester, Minnesota.
Articles by Yi Lin, MD
Panel Highlights Key Myeloma Takeaways From ASCO 2023
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panelists highlight key data presented at ASCO 2023.
View More
What Are the Considerations with Toxicity, Access in BCMA-Directed Bispecifics?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
View More
Panel Discusses Use of Bispecifics to Treat Relapsed/Refractory Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
View More
What Are the Novel BCMA-Targeted CAR-T Therapies in the Myeloma Pipeline?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
View More
Real-World CAR-T Outcomes, Use of Ide-Cel, Cilta-Cel for Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
March 15, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
View More
Panelists Discuss Access to CAR-T for Patients with Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
View More
What Is the Role of BCMA-Targeted CAR-Ts in Late-Relapse Multiple Myeloma?
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
View More
Panel Discusses Maintenance Therapy, the Changing Landscape for Early-Relapse Multiple Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
View More
Early Relapse: Three Versus Four Drugs for Induction in Myeloma
Saad Z. Usmani, MD, MBA, FACP
Video Insights
|
January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
View More